Esplenomegalia em cães: estudo retrospectivo

The aim of this study was to review the prevalence of canine splenic disorders by means of a retrospectiveanalysis of histological diagnosis after splenectomy. The results were confronted with laboratory findings, clinical signs and presence of cardiac arrhythmia and hemoperitoneum, in an attempt to establish the differentialdiagnosis of splenomegaly. One hundred and nine dogs assisted at the Veterinary Hospital of theSchool of Veterinary Medicine and Zootechny, University of São Paulo, were included in the retrospectivestudy, between 2002 and 2009. The average age was 10 years old ± 3, with no sexual predilection. Mixedbreed dogs was the most affected kind, and average weight was 22 kg ± 13. Overall, 52% (57/109) of dogswere splenectomized due to non-neoplastic diseases and 48% (52/109) to neoplastic diseases. Among thelatter, the most common diagnosis was hemangiosarcoma (28 dogs; 54%). Most frequent clinical signs includedanorexia, lethargy and vomiting. Results showed that dogs with low red blood cell count, low hematocritvalues and/or hemoperitoneum were more likely to have splenic malignant neoplasm. On the otherhand, sex, breed, size, age, cardiac arrhythmia and other laboratory parameters were not determining factorsin the differentiation of splenomegaly.

Risk factors for infection with coagulase-negative staphylococci in newborns from the neonatal unit of a brazilian university hospital

Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)

Clinical Assessment of Tribulus terrestris Extract in the Treatment of Female Sexual Dysfunction

This is a qualitative-quantitative study based on hospital records of female patients of reproductive age, presenting sexual dysfunction, and treated with 250 mg Tribulus terrestris extract (1 tablet thrice daily for 90 days). Safety monitoring included vital signs, physical examination, laboratory tests, and occurrence of adverse events. Efficacy analysis included results of the Female Sexual Function Index (FSFI), dehydroepiandrosterone (DHEA) levels together with total and free testosterone, and the patient and physician assessments. There was a statistically significant improvement in total FSFI scores (P < 0.0001) post-treatment, with improvement among 106 (88.33%) subjects. There was a statistically significant (P < 0.0001) increase in the level of DHEA, while the levels of both serum testosterone (P = 0.284) and free testosterone decreased (P < 0.0001). Most adverse events recorded were related to the gastrointestinal tract. Physical examination showed no significant changes post-treatment. Based on the results, it is concluded that the T. terrestris extract is safe and effective in the treatment of female sexual dysfunction.